Prometheus Laboratories is enrolling patients for Proclivity 01, a multi-center study of Proleukin (High Dose Interleukin-2 (HD IL-2)) combined with vemurafenib therapy in patients with Braf V600 mutation-positive metastatic melanoma (mM). ...
Tags: Prometheus, Proclivity 01 Study